FDA Opens Botanical Drug Docket as Appalachia's Wild Ginseng Season Gets Underway Under Federal Trade Controls
The Food and Drug Administration opened a public docket on September 4, seeking input on how to accelerate the development of botanical drug products, which the agency defines as drug products that include or may be derived from plant material, algae, …